Moderna announced the change Wednesday, about a week after revealing that the FDA’s vaccine chief was refusing to review the ...

With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for ...

Moderna announced that the FDA agreed to review its application for a mRNA-based flu vaccine after it agreed to further study ...

Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

The vaccine uses MRNA technology, which health secretary Robert F. Kennedy Jr. has called "unsafe and ineffective." ...

Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.

The Food and Drug Administration has reversed its shocking refusal to consider Moderna’s mRNA flu vaccine for approval.

Moderna said the U.S. Food and Drug Administration has agreed to review its influenza vaccine, reversing an earlier decision to reject the application.

The company’s mRNA flu shot, if approved, could be available for the 2026-27 flu season.

The U.S. Food and Drug Administration says it will review a new mRNA flu vaccine from Moderna. Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the ...